Maturity-Onset Diabetes of the Young
On this page
Direct answer
Three generations of slim, young, non-insulin-dependent diabetics should trigger the thought: MODY — monogenic diabetes inherited in autosomal dominant fashion, presenting under 25 years, and estimated at 1–2% of all diabetes, the vast majority of it mislabelled as type 1 or type 2. The subtypes carry distinct management: GCK-MODY (MODY 2) needs no treatment at all, HNF1A-MODY (MODY 3) responds dramatically to low-dose sulfonylureas, and HNF1B-MODY (MODY 5) comes with renal cysts and uterine anomalies. Making the distinction changes therapy — insulin can be safely withdrawn in HNF1A — so suspicion followed by genetic testing is the clinical skill.
What you must remember
- Diagnostic triad: onset under 25, autosomal dominant inheritance (affected parent in every branch, ~50% of offspring), and absence of autoimmunity/insulin resistance.
- MODY 2 (GCK): lifelong mild fasting hyperglycaemia (roughly 5.5–8 mmol/L), barely rising on OGTT, minimal complications, treatment usually unnecessary.
- MODY 3 (HNF1A): the commonest subtype in many series; progressive post-prandial hyperglycaemia, glycosuria at low renal threshold, sensitive to low-dose sulfonylureas.
- MODY 1 (HNF4A): uncommon; macrosomia at birth may be the first clue; also sulfonylurea-responsive.
- MODY 5 (HNF1B): renal cysts, pancreatic hypoplasia, uterine anomalies, genital malformations — "RCAD" (renal cysts and diabetes); often needs insulin.
- Antibody-negative, C-peptide-positive young diabetes with strong family history is the screening pattern; molecular genetic testing confirms.
- Transient neonatal diabetes versus permanent neonatal diabetes (KCNJ11, ABCC8 — activatable by sulfonylureas) are allied monogenic forms worth knowing by name.
How to work through a suspected case
A 19-year-old student is referred on "insulin, 22 units daily" since age 16. She is slim (BMI 20), has never had ketones, her GAD antibodies were negative at diagnosis, and C-peptide is clearly detectable five years in. Her father, paternal aunt and grandmother all "got diabetes young" and the grandmother now has hearing loss — that maternal-sounding detail aside, three generations with early-onset diabetes is the pedigree that should stop you writing "type 1" again.
The next moves matter more than the label. Check her records for glycosuria out of proportion to modest hyperglycaemia (an HNF1A signature from the low renal threshold), and send HbA1c with a fasting glucose pattern: stable mild fasting values across years since childhood would favour GCK, while a clear upward drift from her mid-teens favours HNF1A. If sequencing confirms HNF1A, the exam-worthy step is therapeutic: transfer insulin to gliclazide 40–80 mg daily — many HNF1A patients achieve control on doses that would barely move a type 2 patient — and insulin is stopped, not tapered, in hospital guidance. If it turns out to be GCK, and she is non-pregnant without complications, the correct prescription is reassurance: her mild hyperglycaemia is a trait, not a disease, and decades of data show low complication rates.
One special situation deserves a vignette of its own: a GCK-mutation mother whose fetus carries the mutation from an unaffected father. Fetal abdominal circumference on serial ultrasound guides whether treatment of maternal glucose is needed at all — over-treating a GCK pregnancy risks starving a mutation-carrying fetus that runs its own, mildly high, set-point.
Where students slip
The reflex "young plus insulin equals type 1" closes the case prematurely and sentences an HNF1A teenager to lifelong injections; the counter-reflex "young plus obese family history equals type 2" is equally common now that adolescent type 2 is widespread. The discriminators examiners reward are concrete: antibody negativity, preserved C-peptide beyond the honeymoon year, slim habitus without acanthosis, a parent affected before 25, and disproportionate glycosuria. A second slip is treating GCK-MODY aggressively — chasing an HbA1c of 6.3% in a GCK patient adds hypoglycaemia without outcome benefit. Finally, candidates forget that MODY 5 announces itself outside the pancreas: an "astute" stem pairs young diabetes with multicystic kidneys or a bicornuate uterus, and the expected answer is HNF1B, not PCOS.
Frequently asked questions
What features distinguish MODY from type 1 diabetes?
Absence of islet autoantibodies, persistent C-peptide beyond the first years, autosomal dominant family history across three generations, and modest insulin requirements in a slim young patient. Genetic testing confirms.
Which MODY subtype requires no pharmacological treatment?
GCK-MODY (MODY 2): a stable, lifelong, mild fasting hyperglycaemia set-point with low complication risk, where diet alone suffices except in specific pregnancy situations.
What is the oral drug of choice in HNF1A-MODY?
A sulfonylurea, often in low dose (gliclazide 40–80 mg), to which HNF1A patients are exquisitely sensitive; many on insulin can switch successfully, though insulin remains fallback during illness or pregnancy planning per specialist advice.
Which MODY presents with renal and genital anomalies?
HNF1B-MODY (MODY 5), part of the renal cysts and diabetes syndrome: renal cysts, hypoplastic kidneys, pancreatic exocrine insufficiency, uterine malformations, and often insulin-requiring diabetes.
How is MODY definitively diagnosed?
Molecular genetic testing — now typically next-generation sequencing panels of monogenic diabetes genes — ideally with pre- and post-test genetic counselling, since results change therapy for the patient and predict risk in relatives.